Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2021 1
2022 4
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Anti-PD-L1 × anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1.
Luangwattananun P, Sangsuwannukul T, Supimon K, Thuwajit C, Chieochansin T, Sa-Nguanraksa D, Samarnthai N, O-Charoenrat P, Junking M, Yenchitsomanus PT. Luangwattananun P, et al. Int Immunopharmacol. 2023 Nov;124(Pt B):111012. doi: 10.1016/j.intimp.2023.111012. Epub 2023 Oct 5. Int Immunopharmacol. 2023. PMID: 37804657
Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.
Yuti P, Sawasdee N, Natungnuy K, Rujirachaivej P, Luangwattananun P, Sujjitjoon J, Yenchitsomanus PT. Yuti P, et al. Among authors: luangwattananun p. Biomed Pharmacother. 2023 Dec;168:115691. doi: 10.1016/j.biopha.2023.115691. Epub 2023 Oct 14. Biomed Pharmacother. 2023. PMID: 37844355 Free article.
Adoptive Transfer of Anti-Nucleolin T Cells Combined with PD-L1 Inhibition against Triple-Negative Breast Cancer.
Thongchot S, Jirapongwattana N, Luangwattananun P, Chiraphapphaiboon W, Chuangchot N, Sa-Nguanraksa D, O-Charoenrat P, Thuwajit P, Yenchitsomanus PT, Thuwajit C. Thongchot S, et al. Among authors: luangwattananun p. Mol Cancer Ther. 2022 May 4;21(5):727-739. doi: 10.1158/1535-7163.MCT-21-0823. Mol Cancer Ther. 2022. PMID: 35313339 Free PMC article.
Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells.
Wathikthinnakon M, Luangwattananun P, Sawasdee N, Chiawpanit C, Lee VS, Nimmanpipug P, Tragoolpua Y, Rotarayanont S, Sangsuwannukul T, Phanthaphol N, Wutti-In Y, Somboonpatarakun C, Chieochansin T, Junking M, Sujjitjoon J, Yenchitsomanus PT, Panya A. Wathikthinnakon M, et al. Among authors: luangwattananun p. Sci Rep. 2022 Apr 13;12(1):6154. doi: 10.1038/s41598-022-09964-6. Sci Rep. 2022. PMID: 35418130 Free PMC article.
11 results